Sanofi buys US biopharma group Blueprint in $9.1 billion deal

Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt, a drug for systemic mastocytosis. The acquisition also includes elenestinib and BLU-808, expanding Sanofi's pipeline. Blueprint shareholders will receive $129.00 per share in cash, plus contingent value rights for potential milestone payments related to BLU-808's development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S4WKIsZ
via IFTTT